|

Cirtuvivint Clinical Trials

4 actively recruiting trials across 3 locations

Pipeline

Phase 1: 2Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Washington University School of Medicine1
  • University of Colorado, Denver1
  • National Cancer Institute (NCI)1
  • Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas1

Indications

  • Cancer4
  • Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia1
  • Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia1
  • Soft Tissue Sarcoma (STS)1
  • Refractory Myelodysplastic Syndrome1

Other1 trial

Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas
Phase 2

Aurora, Colorado1 trial

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

CU Medicine Clinics

Phase 1

New Haven, Connecticut1 trial

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Yale University

Phase 1

St Louis, Missouri1 trial

Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

Washington University School of Medicine

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.